← Leaderboards
Katerina Abigail Politi
Yale University
$13,632,706
Attributed
$19,689,654
Total exposure
13
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,504,524 · 14
By mechanism
P50$12,765,136 · 6
R01$10,681,437 · 4
U01$3,868,773 · 1
R00$732,060 · 1
K99$278,592 · 1
P30$178,526 · 1
Top collaborators
- Susan M Kaech9 shared
- Roy S Herbst5 shared
- Don X Nguyen5 shared
- Monte Meier Winslow5 shared
- Mandar Deepak Muzumdar1 shared
- Siyuan Wang1 shared
Most similar at Yale University
Same institution · by research overlap
- Paul Forscher$9,615,812
- Don X Nguyen$10,390,286
- Michael H Nathanson$44,568,855
- Jeremy Baskin$6,527,425
- Peter Tattersall$24,230,327
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungTumorMutationResistanceMutantEpidermal Growth Factor ReceptorMouse ModelResponsePathway InteractionsMolecularTyrosine Kinase InhibitorMalignant NeoplasmsLung AdenocarcinomaDrug ResistanceTargeted TreatmentProgramsCellsGenesMediatingResistance MechanismLung NeoplasmsOncogenicInsightCessation Of Life
Grant awards (50)
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer$2,341,652
P50 · FY2025 · CA
Genetic Determinants of Tumor Growth and Drug Sensitivity in EGFR Mutant Lung Cancer$551,847
R01 · FY2025 · CA · contact PI
Project 2: Optimizing Precision Medicine Approaches to Treat EGFR-Driven Lung Cancer$415,078
P50 · FY2025 · CA · contact PI
Cancer Signaling Networks Research Program$97,007
P30 · FY2025 · CA · contact PI
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer$2,137,785
P50 · FY2024 · CA
Genetic Determinants of Tumor Growth and Drug Sensitivity in EGFR Mutant Lung Cancer$536,716
R01 · FY2024 · CA · contact PI
Project 2: Mechanism-based approaches to counter TKI resistance in EGFR mutant lung cancer$389,539
P50 · FY2024 · CA · contact PI
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer$218,588
P50 · FY2024 · CA
Project 2: Mechanism-based approaches to counter TKI resistance in EGFR mutant lung cancer$218,588
P50 · FY2024 · CA · contact PI
Cancer Signaling Networks Research Program$81,519
P30 · FY2024 · CA · contact PI
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer$2,069,846
P50 · FY2023 · CA
Uncovering the Biology of Resistance to Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Patient-Derived Models.$728,983
U01 · FY2023 · CA · contact PI
Understanding and Overcoming Resistance to Cancer Immunotherapy Due to Defective Antigen Presentation$641,997
R01 · FY2023 · CA · contact PI
Genetic Determinants of Tumor Growth and Drug Sensitivity in EGFR Mutant Lung Cancer$558,923
R01 · FY2023 · CA · contact PI
Project 2: Mechanism-based approaches to counter TKI resistance in EGFR mutant lung cancer$392,909
P50 · FY2023 · CA · contact PI
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer$2,046,999
P50 · FY2022 · CA
Uncovering the Biology of Resistance to Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Patient-Derived Models.$749,308
U01 · FY2022 · CA · contact PI
Understanding and Overcoming Resistance to Cancer Immunotherapy Due to Defective Antigen Presentation$655,529
R01 · FY2022 · CA · contact PI
Genetic Determinants of Tumor Growth and Drug Sensitivity in EGFR Mutant Lung Cancer$561,463
R01 · FY2022 · CA · contact PI
Project 2: Mechanism-based approaches to counter TKI resistance in EGFR mutant lung cancer$374,058
P50 · FY2022 · CA · contact PI
Uncovering the Biology of Resistance to Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Patient-Derived Models.$778,382
U01 · FY2021 · CA · contact PI
Understanding and Overcoming Resistance to Cancer Immunotherapy Due to Defective Antigen Presentation$682,315
R01 · FY2021 · CA · contact PI
Genetic Determinants of Tumor Growth and Drug Sensitivity in EGFR Mutant Lung Cancer$604,225
R01 · FY2021 · CA · contact PI
Project 2: Mechanism-based approaches to counter TKI resistance in EGFR mutant lung cancer$385,459
P50 · FY2021 · CA · contact PI
Uncovering the Biology of Resistance to Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Patient-Derived Models.$798,050
U01 · FY2020 · CA · contact PI
Understanding and Overcoming Resistance to Cancer Immunotherapy Due to Defective Antigen Presentation$695,333
R01 · FY2020 · CA · contact PI
Project 2: Mechanism-based approaches to counter TKI resistance in EGFR mutant lung cancer$386,738
P50 · FY2020 · CA · contact PI
Uncovering the Biology of Resistance to Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Patient-Derived Models.$814,050
U01 · FY2019 · CA · contact PI
Understanding and Overcoming Resistance to Cancer Immunotherapy Due to Defective Antigen Presentation$734,862
R01 · FY2019 · CA · contact PI
Targeting the EGFR Pathway in Lung Adenocarcinoma$316,762
P50 · FY2019 · CA · contact PI
Understanding and Overcoming Resistance to Cancer Immunotherapy Due to Defective Antigen Presentation$240,500
R01 · FY2019 · CA · contact PI
Targeting the EGFR Pathway in Lung Adenocarcinoma$250,489
P50 · FY2018 · CA · contact PI
Targeting the Immune System in Mouse Models of Lung Adenocarcinoma$579,271
R01 · FY2017 · CA · contact PI
Targeting the EGFR Pathway in Lung Adenocarcinoma$352,755
P50 · FY2017 · CA · contact PI
Targeting the Immune System in Mouse Models of Lung Adenocarcinoma$591,863
R01 · FY2016 · CA · contact PI
Targeting the EGFR Pathway in Lung Adenocarcinoma$236,688
P50 · FY2016 · CA · contact PI
Targeting the Immune System in Mouse Models of Lung Adenocarcinoma$610,279
R01 · FY2015 · CA · contact PI
Targeting the EGFR Pathway in Lung Adenocarcinoma$231,203
P50 · FY2015 · CA · contact PI
Mutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic Mice$286,975
R01 · FY2014 · CA · contact PI
Mutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic Mice$277,230
R01 · FY2013 · CA · contact PI
Mutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic Mice$293,295
R01 · FY2012 · CA · contact PI
Mechanisms of Mutant Epidermal Growth Factor Receptor Induced Lung Tumorigenesis$241,530
R00 · FY2012 · CA · contact PI
Mutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic Mice$307,134
R01 · FY2011 · CA · contact PI
Mechanisms of Mutant Epidermal Growth Factor Receptor Induced Lung Tumorigenesis$241,530
R00 · FY2011 · CA · contact PI
Mutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic Mice$383,570
R01 · FY2010 · CA · contact PI
Mechanisms of Mutant Epidermal Growth Factor Receptor Induced Lung Tumorigenesis$249,000
R00 · FY2010 · CA · contact PI
Mutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic Mice$493,144
R01 · FY2009 · CA · contact PI
Mutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic Mice$394,966
R01 · FY2009 · CA · contact PI
Mechanisms of Mutant Epidermal Growth Factor Receptor Induced Lung Tumorigenesis$139,296
K99 · FY2009 · CA · contact PI
Mechanisms of Mutant Epidermal Growth Factor Receptor Induced Lung Tumorigenesis$139,296
K99 · FY2008 · CA · contact PI